OncoImmune Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $678M

OncoImmune General Information

Description

Operator of a clinical-stage biopharmaceutical company engaged in the discovery and development of novel biopharmaceuticals for the treatment of cancer and autoimmune disease. The company's offerings include recombinant fusion protein that targets a novel immune pathway checkpoint, enabling doctors to help treat diseases targeting the immune system.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 9430 Key West Avenue
  • Suite 113
  • Rockville, MD 20850
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 9430 Key West Avenue
  • Suite 113
  • Rockville, MD 20850
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OncoImmune Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 01-Dec-2020 $678M Completed Clinical Trials - Phase 3
7. Later Stage VC (Series B) 09-Sep-2020 Completed Clinical Trials - Phase 3
6. Later Stage VC (Series A1) 22-May-2020 Completed Clinical Trials - Phase 3
5. Grant 01-Jan-2020 Completed Clinical Trials - Phase 2
4. Grant 01-Jan-2019 Completed Clinical Trials - Phase 2
3. Later Stage VC (Series A) 12-Jan-2017 Completed Clinical Trials - Phase 2
2. Grant 01-Jan-2017 $2M Completed Clinical Trials - Phase 2
1. Early Stage VC 01-Jan-2004 Completed Startup
To view OncoImmune’s complete valuation and funding history, request access »

OncoImmune Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A1
Series A 2,601,833 $0.000100 $3.84 $3.84 1x $3.84 4.52%
To view OncoImmune’s complete cap table history, request access »

OncoImmune Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage biopharmaceutical company engaged in the discovery and development of novel biopharmaceutic
Drug Discovery
Rockville, MD

San Diego, CA
 

Somerville, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

OncoImmune Competitors (2)

One of OncoImmune’s 2 competitors is Sorrento Therapeutics, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sorrento Therapeutics Formerly VC-backed San Diego, CA
Genetix Biotherapeutics Private Equity-Backed Somerville, MA
You’re viewing 2 of 2 competitors. Get the full list »

OncoImmune Patents

OncoImmune Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230103352-A1 Methods of use of soluble cd24 for treating sars-cov-2 infection Inactive 24-Sep-2020
US-20230108492-A1 Methods of use of soluble cd24 for treating viral pneumonia Inactive 09-Apr-2020
EP-4103218-A1 Methods of use of soluble cd24 for treating sars-cov-2 infection Inactive 10-Feb-2020
EP-4103218-A4 Methods of use of soluble cd24 for treating sars-cov-2 infection Inactive 10-Feb-2020
WO-2021160170-A1 Methods of use of soluble cd24 for treating sars-cov-2 infection Inactive 10-Feb-2020 A61K38/177
To view OncoImmune’s complete patent history, request access »

OncoImmune Former Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
3E Bioventures (China) Venture Capital Minority
Falcon Creek Capital Venture Capital Minority
GBA Capital PE/Buyout Minority
GF Xinde Investment Management PE/Buyout Minority
HM Capital Venture Capital Minority
You’re viewing 5 of 12 investors. Get the full list »

OncoImmune FAQs

  • When was OncoImmune founded?

    OncoImmune was founded in 2000.

  • Where is OncoImmune headquartered?

    OncoImmune is headquartered in Rockville, MD.

  • What industry is OncoImmune in?

    OncoImmune’s primary industry is Drug Discovery.

  • Is OncoImmune a private or public company?

    OncoImmune is a Private company.

  • What is the current valuation of OncoImmune?

    The current valuation of OncoImmune is .

  • What is OncoImmune’s current revenue?

    The current revenue for OncoImmune is .

  • How much funding has OncoImmune raised over time?

    OncoImmune has raised $74M.

  • Who are OncoImmune’s investors?

    3E Bioventures (China), Falcon Creek Capital, GBA Capital, GF Xinde Investment Management, and HM Capital are 5 of 12 investors who have invested in OncoImmune.

  • Who are OncoImmune’s competitors?

    Sorrento Therapeutics and Genetix Biotherapeutics are competitors of OncoImmune.

  • When was OncoImmune acquired?

    OncoImmune was acquired on 01-Dec-2020.

  • Who acquired OncoImmune?

    OncoImmune was acquired by Merck & Co..

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process